deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07043270

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

24BRO681 : Neoadjuvant Therapy With Alternating Gemcitabine Plus Nab-Paclitaxel and mFOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial

Sponsor: Dartmouth-Hitchcock Medical Center

Conditions Pancreas Adenocarcinoma
Interventions Nab-paclitaxel + Gemcitabine modified FOLFIRINOX (mFOLFIRINOX)
Updated 3 times since 2025 Last updated: Oct 16, 2025 Started: Sep 29, 2025 Primary completion: Jul 1, 2028 Completion: Jul 1, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07043270, this PHASE2 trial focuses on Pancreas Adenocarcinoma and remains actively recruiting participants. Sponsored by Dartmouth-Hitchcock Medical Center, it has been updated 3 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshotNot Yet Recruiting~Aug 2025 – ~Nov 2025 · 3 months · monthly snapshotNot Yet Recruiting~Nov 2025 – present · 8 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Nov 2025 — Present [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  2. Aug 2025 — Nov 2025 [monthly]

    Not Yet Recruiting PHASE2

  3. Jul 2025 — Aug 2025 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dartmouth-Hitchcock Medical Center
Data source: Dartmouth-Hitchcock Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations